Published in J Clin Oncol on January 01, 1993
Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. Lancet Oncol (2012) 2.65
Clinical course and prognostic factors following bone recurrence from breast cancer. Br J Cancer (1998) 2.20
The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer (2001) 2.14
Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer (2000) 2.12
Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res (2006) 1.71
Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ (2003) 1.60
Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest (1996) 1.44
Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer (2004) 1.38
Bone-targeted agents and skeletal-related events in breast cancer patients with bone metastases: the state of the art. Curr Oncol (2012) 1.37
Metabolic effects of pamidronate in patients with metastatic bone disease. Br J Cancer (1996) 1.19
Meta-analysis of clodronate and breast cancer survival. Br J Cancer (2007) 1.06
Bisphosphonates antagonise bone growth factors' effects on human breast cancer cells survival. Br J Cancer (2003) 1.05
Bisphosphonates in oncology: evidence for the prevention of skeletal events in patients with bone metastases. Drug Des Devel Ther (2009) 1.03
High-dose intravenous pamidronate for metastatic bone pain. Br J Cancer (1994) 1.03
Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens. Br J Cancer (1997) 0.94
Skeletal metastases from breast cancer: pathogenesis of bone tropism and treatment strategy. Clin Exp Metastasis (2015) 0.94
Palliative care. BMJ (1994) 0.93
Bisphosphonates for malignancy-related bone disease: current status, future developments. Support Care Cancer (2006) 0.93
Bisphosphonates in Breast Cancer Patients with Bone Metastases. Breast Care (Basel) (2010) 0.91
Recent developments in bisphosphonates for patients with metastatic breast cancer. BMJ (2005) 0.86
Effectiveness of bisphosphonates on bone pain and quality of life in breast cancer patients with metastatic bone disease: a review. Support Care Cancer (2007) 0.86
Optimizing clinical benefits of bisphosphonates in cancer patients with bone metastases. Oncologist (2010) 0.86
Clinical role of bisphosphonate therapy. Int J Womens Health (2012) 0.85
The present and future role of bisphosphonates in the management of patients with breast cancer. Breast Cancer Res (2001) 0.85
A prospective analysis of CT density measurements of bone metastases after treatment with zoledronic acid. Skeletal Radiol (2007) 0.84
A primer of bone metastases management in breast cancer patients. Curr Oncol (2008) 0.84
Pharmacologic inhibition of bone resorption prevents cancer-induced osteolysis but enhances soft tissue metastasis in a mouse model of osteolytic breast cancer. Int J Oncol (2014) 0.81
Utilization of palliative radiotherapy for breast cancer patients with bone metastases treated with bisphosphonates-Toronto Sunnybrook Regional Cancer Centre experience. Support Care Cancer (2003) 0.80
Bone antiresorptive agents in the treatment of bone metastases associated with solid tumours or multiple myeloma. Bonekey Rep (2015) 0.79
Potential for Early Fracture Risk Assessment in Patients with Metastatic Bone Disease using Parametric Response Mapping of CT Images. Tomography (2015) 0.78
Bisphosphonates in the adjuvant treatment of cancer: experimental evidence and first clinical results. International Bone and Cancer Study Group (IBCG). Br J Cancer (2000) 0.78
Management strategies for chronic pain. Ann Rheum Dis (1996) 0.77
Importance of antiresorptive therapies for patients with bone metastases from solid tumors. Cancer Manag Res (2012) 0.76
Bone-Targeted Agents for the Management of Breast Cancer Patients with Bone Metastases. J Clin Med (2013) 0.76
Treatment of severe, recalcitrant reflex sympathetic dystrophy: assessment of efficacy and safety of the second generation bisphosphonate pamidronate. Clin Rheumatol (1997) 0.76
Molecular Mechanisms of Bone Metastasis: Which Targets Came from the Bench to the Bedside? Int J Mol Sci (2016) 0.75
Comparing the results of bisphosphonate use in clinical trials with actual practice: a case of apples and oranges? Curr Oncol (2006) 0.75
Differential effect of zoledronic acid on normal trabecular and cortical bone density in oncologic patients with bone metastases. J Bone Oncol (2012) 0.75
Events per person year. A decrease in multiple events may be missed. BMJ (1995) 0.75
Informed consent in clinical trials. Full consent may bias outcome of trials. BMJ (1993) 0.75
Use of ibandronate in the prevention of skeletal events in metastatic breast cancer. Ther Clin Risk Manag (2008) 0.75
Efficacy and tolerability of medical ozone gas insufflations in patients with osteonecrosis of the jaw treated with bisphosphonates-Preliminary data: Medical ozone gas insufflation in treating ONJ lesions. J Bone Oncol (2012) 0.75
Clinical features of metastatic cancer in primary care: a case-control study using medical records. Br J Gen Pract (2015) 0.75
Improving management of patients with advanced cancer. Patient Prefer Adherence (2010) 0.75
Bone targeted treatments in cancer - The story so far. J Bone Oncol (2016) 0.75
Bones, breasts, and bisphosphonates: rationale for the use of zoledronic acid in advanced and early breast cancer. Breast Cancer (Dove Med Press) (2011) 0.75
Intravenous pamidronate versus oral and intravenous clodronate in bone metastatic breast cancer: a randomized, open-label, non-inferiority Phase III trial. Onco Targets Ther (2016) 0.75
Bone Health in Patients with Breast Cancer: Recommendations from an Evidence-Based Canadian Guideline. J Clin Med (2013) 0.75
Incidence and outcome of bone metastatic disease at University Malaya Medical Centre. Singapore Med J (2014) 0.75
Bisphosphonates as adjuvant treatment for breast cancer. BMJ (2002) 0.75
Prevention and Treatment of Bone Metastases in Breast Cancer. J Clin Med (2013) 0.75
Recent advances in the systemic therapy of breast cancer. Ochsner J (2000) 0.75
Bisphosphonates for bone metastatic disease from breast cancer: clinical practice in the Czech Republic. Clin Exp Metastasis (2007) 0.75
Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res (1987) 24.27
An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int (2006) 11.05
FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int (2008) 8.75
World-wide projections for hip fracture. Osteoporos Int (1997) 6.83
The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int (2007) 6.44
Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int (2005) 5.54
Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet (1998) 5.35
Dual-energy x-ray absorptiometry for total-body and regional bone-mineral and soft-tissue composition. Am J Clin Nutr (1990) 4.82
Occurrence, causes, and outcome of delirium in patients with advanced cancer: a prospective study. Arch Intern Med (2000) 4.60
Overview of the main outcomes in breast-cancer prevention trials. Lancet (2003) 4.31
An estimate of the worldwide prevalence, mortality and disability associated with hip fracture. Osteoporos Int (2004) 4.24
Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet (1994) 4.03
Mortality after osteoporotic fractures. Osteoporos Int (2003) 3.68
Bone densitometry in clinical practice. BMJ (1995) 3.48
Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int (2010) 3.36
The prevalence of vertebral deformity in european men and women: the European Vertebral Osteoporosis Study. J Bone Miner Res (1996) 3.25
Incidence of vertebral fracture in europe: results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res (2002) 3.16
Secular trends in the incidence of hip and other osteoporotic fractures. Osteoporos Int (2011) 3.04
Failure of chemotherapy to prolong survival in a group of patients with metastatic breast cancer. Lancet (1980) 2.82
Direct in vivo assessment of microcirculatory dysfunction in severe falciparum malaria. J Infect Dis (2008) 2.77
Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol (1996) 2.76
Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas (2009) 2.74
Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol (1998) 2.73
A global representation of vitamin D status in healthy populations. Arch Osteoporos (2012) 2.69
The assessment of vertebral deformity: a method for use in population studies and clinical trials. Osteoporos Int (1993) 2.66
The management of histologically unverified presumed cerebral gliomas with radiotherapy. Int J Radiat Oncol Biol Phys (1994) 2.65
Declines in HIV prevalence can be associated with changing sexual behaviour in Uganda, urban Kenya, Zimbabwe, and urban Haiti. Sex Transm Infect (2006) 2.65
Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol (2008) 2.46
Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J Clin Pathol (2006) 2.40
Bone-density measurement. Lancet (1992) 2.38
Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol (1999) 2.32
Family history of breast cancer: what do women understand and recall about their genetic risk? J Med Genet (1998) 2.27
Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat (2001) 2.26
Pitfalls in the external validation of FRAX. Osteoporos Int (2011) 2.21
Fracture risk following an osteoporotic fracture. Osteoporos Int (2003) 2.21
Quality of life in patients with vertebral fractures: validation of the Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO). Working Party for Quality of Life of the European Foundation for Osteoporosis. Osteoporos Int (1999) 2.20
A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol (1998) 2.18
Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ (1995) 2.10
Detection of micrometastases in patients with primary breast cancer. Lancet (1983) 2.07
Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route. Cancer Res (1987) 2.03
Comparison of two different concentrations of hyaluronidase in patients receiving one-hour infusions of hypodermoclysis. J Pain Symptom Manage (1995) 2.00
Subcutaneous morphine for dyspnea in cancer patients. Ann Intern Med (1993) 1.95
Evidence from electron microscope studies on actin paracrystals concerning the origin of the cross-striation in the thin filaments of vertebrate skeletal muscle. Proc R Soc Lond B Biol Sci (1973) 1.93
Breast-cancer osteolysis, bone metastases, and anti-osteolytic effect of aspirin. Lancet (1976) 1.92
Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann Oncol (2003) 1.92
Herpes simplex type 1 induction of persistent NF-kappa B nuclear translocation increases the efficiency of virus replication. Virology (1998) 1.91
Assessment of biochemical tests to screen for metastases in patients with breast cancer. Lancet (1980) 1.88
Risk of vertebral fracture in women with rheumatoid arthritis. BMJ (1993) 1.87
Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br J Cancer (2004) 1.87
Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporos Int (2010) 1.83
Matching and maximizing with concurrent ratio-interval schedules. J Exp Anal Behav (1983) 1.83
Treatment failure in osteoporosis. Osteoporos Int (2012) 1.82
The apparent incidence of hip fracture in Europe: a study of national register sources. Osteoporos Int (1992) 1.81
The inhibition by aspirin and indomethacin of osteolytic tumor deposits and hypercalcaemia in rats with Walker tumour, and its possible application to human breast cancer. Br J Cancer (1973) 1.81
Survey of treatment of primary breast cancer in Great Britain. Br Med J (Clin Res Ed) (1985) 1.80
Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. Cancer Res (1991) 1.80
Risk factors for hip fracture in European women: the MEDOS Study. Mediterranean Osteoporosis Study. J Bone Miner Res (1995) 1.79
Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX). Osteoporos Int (2008) 1.77
Biological control of crystal texture: a widespread strategy for adapting crystal properties to function. Science (1993) 1.76
Symptom control during the last week of life on a palliative care unit. J Palliat Care (1991) 1.75
A high incidence of vertebral fracture in women with breast cancer. Br J Cancer (1999) 1.74
Assessment of response of bone metastases to systemic treatment in patients with breast cancer. Cancer (1983) 1.73
Osteoporosis in the European Union: a compendium of country-specific reports. Arch Osteoporos (2013) 1.72
Preventable deaths after injury: why are the traditional 'vital' signs poor indicators of blood loss? J Accid Emerg Med (1995) 1.71
Health-related quality of life and radiographic vertebral fracture. Osteoporos Int (2003) 1.70
Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int (2010) 1.69
Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers? Br J Cancer (2004) 1.69
Hospital stay following biliary tract surgery. A comparison of two community hospitals. Arch Surg (1986) 1.69
Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease. Lancet (1980) 1.68
Primary breast lymphoma. An immunohistologic study of 20 new cases. Cancer (1990) 1.65
Risk of second brain tumour after conservative surgery and radiotherapy for pituitary adenoma. BMJ (1992) 1.63
Rate of reversal of hypercalcaemia and hypercalciuria induced by vitamin D and its 1alpha-hydroxylated derivatives. Br Med J (1977) 1.62
Tamoxifen for the prevention of breast cancer. Eur J Cancer (2000) 1.62
Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol (2001) 1.61
The distribution, determinants, and clinical correlates of vertebral osteophytosis: a population based survey. J Rheumatol (1999) 1.60
Good clinical response of breast cancers to neoadjuvant chemoendocrine therapy is associated with improved overall survival. Ann Oncol (2005) 1.59
Number and type of vertebral deformities: epidemiological characteristics and relation to back pain and height loss. European Vertebral Osteoporosis Study Group. Osteoporos Int (1999) 1.59
Frailty and sarcopenia: definitions and outcome parameters. Osteoporos Int (2012) 1.58
Surgical experience and supervision may influence the quality of lower limb amputation. Ann R Coll Surg Engl (2002) 1.57
Incidence of limb fracture across Europe: results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int (2002) 1.56
A double-blind study of deflazacort and prednisone in patients with chronic inflammatory disorders. Arthritis Rheum (1991) 1.56
Vitamin D supplementation in elderly or postmenopausal women: a 2013 update of the 2008 recommendations from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Curr Med Res Opin (2013) 1.55
Short-term results of femoropopliteal subintimal angioplasty. Br J Surg (2000) 1.54
A comparison of patient and proxy symptom assessments in advanced cancer patients. Palliat Med (1999) 1.52
Local relapse in primary breast cancer patients with unexcised positive surgical margins after lumpectomy, radiotherapy and chemoendocrine therapy. Ann Oncol (1999) 1.51
Breast cancer in northern Alberta: pilot study in computerized registration. Can Med Assoc J (1977) 1.51
Is 24,25-dihydroxycholecalciferol a calcium-regulating hormone in man? Br Med J (1978) 1.49
Prospective single blinded randomised controlled trial of two orally administered activated charcoal preparations. J Accid Emerg Med (1999) 1.49
Evaluation of a nurse-led telephone clinic in the follow-up of patients with malignant glioma. Clin Oncol (R Coll Radiol) (2000) 1.49
Biochemical markers in human breast cancer. Lancet (1977) 1.48
Improved cure rate in children with B-cell acute lymphoblastic leukaemia (B-ALL) and stage IV B-cell non-Hodgkin's lymphoma (B-NHL)--results of the UKCCSG 9003 protocol. Br J Cancer (1998) 1.48
Use of diphosphonates in hypercalcaemia due to malignancy. Lancet (1990) 1.47
c-erbB-2 expression in benign and malignant breast disease. Br J Cancer (1988) 1.47